Emerging immune checkpoints for cancer therapy (Q38584979)

4 September 2017

Emerging immune checkpoints for cancer therapy (English)

1 reference

4 September 2017

Xiaodong Li

1

1 reference

4 September 2017

Wenwei Hu

2

1 reference

4 September 2017

Xiao Zheng

3

1 reference

4 September 2017

Chu Zhang

4

1 reference

4 September 2017

Peng Du

5

1 reference

4 September 2017

Zhuojun Zheng

6

1 reference

4 September 2017

Yan Yang

7

1 reference

4 September 2017

Jun Wu

8

1 reference

4 September 2017

Mei Ji

9

1 reference

4 September 2017

Jingting Jiang

10

1 reference

4 September 2017

Changping Wu

11

1 reference

4 September 2017

11 September 2015

1 reference

4 September 2017

1 reference

4 September 2017

54

1 reference

4 September 2017

10

1 reference

4 September 2017

1706-1713

1 reference

Nivolumab plus ipilimumab in advanced melanoma

4 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Immunotherapy for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

LAG-3, a novel lymphocyte activation gene closely related to CD4

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Clinical impact of checkpoint inhibitors as novel cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Role of LAG-3 in regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

LAG-3 regulates plasmacytoid dendritic cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

CTLA-4 regulates cell cycle progression during a primary immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tim-3, a negative regulator of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Prospects for TIM3-Targeted Antitumor Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tim-3 expression defines regulatory T cells in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tim-3 expression in cervical cancer promotes tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Emerging Tim-3 functions in antimicrobial and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Therapeutic gene modified cell based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Targeting regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

TIMs: central regulators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The expression of Tim-3 in peripheral blood of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Analysis of Tim-3 as a therapeutic target in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

Managing immune checkpoint-blocking antibody side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2015.1071918

10.3109/0284186X.2015.1071918

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference